BRIEF—Lucentis usability data support approval in ophthalmology

A new  analysis of the usability of Lucentis (ranibizumab injection) found that medical professionals were able to successfully administer the therapy, with 91% reporting they found the Lucentis PFS “easy” or “very easy” to use.

Roche subsidiary Genentech markets Lucentis in the USA and won approval from the US Food and Drug Administration in October 2016 for the therapy, the first syringe prefilled with an anti-VEGF medicine for wet age-related macular degeneration (AMD). Novartis markets Lucentis to the UK and the rest of the world

The firm says the results led to the FDA approving the formulation in March 2018 to treat all forms of diabetic retinopathy in people with or without diabetic macular edema (DME).